Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?

Cancers (Basel) · 2025 · PMC12427405 · PMID 40940908

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the primary endpoint did not reach statistical significance, the intention-to-treat analysis of OS, adjusted for stratification factors and other prognostic factors such as nodal status, grade of disease, and sex, showed some benefits in the capecitabine arm.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.